title: [Application of HPLC to meropenem determination in plasma samples of patients with infections treated after coronary artery bypass graft surgery].
abstract: In performed study the effectiveness of meropenem administration was estimated after therapeutic using in infections treatment after coronary artery bypass graft surgery on the base of antibiotic concentrations determined by HPLC method in the plasma samples of patients. The aim of the present study was to determine pharmacokinetic parameters of meropenem in patients' plasma samples after multiple intravenous antibiotic administration and the estimation of meropenem concentrations to MIC of bacterial pathogens. The biological material to our study was taken in 2; 4; 5 and 6 day of the antibiotic therapy. The solid phase extraction was used to the isolation of meropenem from the plasma samples. Applied chromatographic conditions of antibiotic included the column LiChrisopher 100 RP-18 (5 microm, 250 mm x 4 mm); the mobile phase comprised phosphate buffer pH 7,0/acetonitrile (92:8); DAD with detection at 296 nm. The maximal meropenem concentration in the steady state (Css(max)) in 2 day of treatment 0.25 h after administration of the next dose of antibiotic was 17.58 microg/ml. In the plasma samples which were taken in the end of the dosage regimen (8 h) in subsequent days the antibiotic was not fund. Only in one patient the minimal concentration in the steady state (Css(min)) was 0.87-0.89 microg/ml and exceeded MIC for Staphylococcus aureus, Enterobacter Escherichia coli i Serratia. The shorter frequency of drug administration has to be consider to assure the therapeutic range of antibiotic concentrations.
authors.affiliation: Katedra i Zakład Chemii i Analizy Leków, Slaski Uniwersytet Medyczny w Katowicach, Sosnowiec. jbafeltowska@sum.edu.pl
authors.forename: Jolanta
authors.initials: J
authors.lastname: Bafeltowska
authors.forename: Agata
authors.initials: A
authors.lastname: Pokorska
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Białek
authors.forename: Mirosław
authors.initials: M
authors.lastname: Wilczyński
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002851:Chromatography, High Pressure Liquid; D001026:Coronary Artery Bypass; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011044:Poland; D018805:Sepsis / Q000188:drug therapy* / Q000378:metabolism; D013845:Thienamycins / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; D000077731:Meropenem